No Data
[Brokerage Focus] CITIC SEC: The integration of the Traditional Chinese Medicine Industry is accelerating, and the leading players are expected to strengthen their position.
Jinwu Financial News | CITIC SEC states that the price of Traditional Chinese Medicine materials has entered a downward channel, and improvements in industrial costs are worth anticipating. Starting in January 2025, Traditional Chinese Medicine companies will successively complete inventory clearance through channels, and numerous e-commerce activities will occur during the Spring Festival, with strong purchasing power among Consumers. The e-commerce platforms' sales of Pharmaceutical products generally achieve high year-on-year growth rates. Benefiting from policy support and the accelerated aging of the population, the bank expects that overall demand for Traditional Chinese Medicine will continue to improve in the future, with industry consolidation accelerating, and leading companies are likely to become stronger.
Hong Kong stock Concept tracking | Promoting the value assessment and allocation of Traditional Chinese Medicine Pharmaceuticals, Institutions are Bullish on the recovery of Traditional Chinese Medicine revenue (with attached Concept stocks)
The General Office of the State Council issued the "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry."
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
JBM (Healthcare) Unit to Buy 90% Stake in Medicine Maker
Hong Kong stock announcement for treasure hunting | STANCHART (02888) released its full-year performance for 2024, with revenue increasing by 14% year-on-year to 19.7 billion USD, setting a historical high.
Great Wall Motor (02333) plans to acquire the remaining 80% stake in Wuxi Xindong to enhance industry synergy and overall competitiveness……
Gelonghui Announcement Highlights (Hong Kong Stocks) | CHINA RE (01508.HK) Profit Upgrade: Expected net income growth of approximately 80% to 100% for the 2024 fiscal year.
【Today's Focus】CHINA RE (01508.HK) announces positive profit news: Expected net income growth of approximately 80% to 100% in 2024. CHINA RE (01508.HK) announced that the net income attributable to the parent company's shareholders for 2024 is expected to increase by approximately 80% to 100% compared to the same period in 2023. The main reason for the group's projected performance improvement in 2024 is the company's adherence to the operational philosophy of 'development with scale, efficient underwriting, and stable investment,' which leads to continuous improvement in underwriting performance and a year-on-year increase in investment returns. 【Significant Matters】CGN POWER (018
